in pictures and a few words
What it is and why it matters
This is a well-known book by a neurologist about how sugar, gluten and metabolism are linked to brain health.
- The main idea: you can care for the brain through metabolism
- Here is what from the book held up in people, and how to apply it
The brain and sugar
In Alzheimer’s disease the brain responds worse to insulin — the hormone that helps cells take sugar from the blood. That is why it is sometimes called “type 3 diabetes”.
- Brain cells run short of energy
- This begins many years before the first signs
Blood sugar can be influenced
The higher the blood sugar — even below the diabetes level — the higher the risk of dementia. The good news: blood sugar can be influenced.
- Sugar and refined starches — keep to a minimum
- Beans and lentils, vegetables, whole grains, fruit with the skin — keep
Blood tests — a foundation for the brain
The brain needs a solid foundation: steady sugar, insulin that works well, normal blood fats. This matters most if Alzheimer’s disease ran in the family or there is an inherited tendency to it.
- Average blood sugar over recent months
- How well insulin works
- Blood fats, omega-3 and vitamin D
Gluten: when it matters
There is a disease in which gluten does harm — coeliac disease: gluten is given up for life. And some people without it have gluten sensitivity: they feel better without gluten.
- Coeliac disease is found with a blood test: for gut complaints, anaemia with no cause
- And also with thyroid inflammation, depression, nerve damage, infertility
- Test is normal but suspicion remains — a doctor may suggest a trial without gluten
Ketones — a backup fuel
When there is no food for a long time or few carbohydrates, the body makes ketones — a backup fuel. The brain can use it without the help of insulin.
- In early Alzheimer’s disease the brain takes up sugar worse, but ketones as before
- A gentle way: fish, olive oil, nuts and a 12–14 hour break from eating
A strict keto diet is a treatment
A strict keto diet is a treatment tool, not a lifestyle. A doctor prescribes it when there is a reason and under supervision.
- Insulin works poorly and metabolism is already disturbed — short courses of 6–12 weeks
- Early memory problems with an inherited tendency — under a doctor’s supervision
- For healthy people, less sugar and refined carbs is enough for prevention
Who a keto diet does not suit
A strict keto diet does not suit everyone. Discuss it with a doctor first.
- Underactive thyroid: with few carbohydrates there is less of its active hormone
- Diseases of the adrenal glands, bile ducts and rare metabolic diseases
- In women of childbearing age the cycle may be disrupted
Important. On a long keto diet, shifts in blood fats, kidney function and gut flora are possible — a doctor’s monitoring is needed.
Who should see a doctor first
If dementia is already present, a neurologist leads the treatment: this book is not about treating it. If you don’t have diabetes and your blood sugar is repeatedly below 3.0 mmol/L (54 mg/dL) or above 8.9 mmol/L (160 mg/dL), see a doctor.
- Don’t drop gluten on your own without tests: for many, meals get poorer with no benefit
- A trial without gluten and its return — only under a doctor’s supervision
- A strict keto diet for memory problems — only when indicated and with monitoring
Important. If Alzheimer’s disease ran in your family, discuss blood tests for sugar, insulin and blood fats with a doctor.
In one sentence
Steady sugar matters for the brain: fewer sweets and refined carbohydrates, more whole food. Cutting out gluten or going on a strict keto diet — only based on tests and with a doctor.
Key points
David Perlmutter is a practising neurologist in Naples (Florida) and a Fellow of the American College of Nutrition; his book "Grain Brain" (Little, Brown, 2013) was a #1 New York Times bestseller that brought the concept of brain metabolic health to a mass audience — here are its main ideas.
| Idea of the book | How it helps a person | What human studies showed |
|---|---|---|
| Alzheimer's disease is in large part a metabolic disease of the brain associated with insulin resistance ("type 3 diabetes") | neurodegeneration begins decades before clinical signs and is modifiable by metabolic means, so metabolic health is the priority for primary prevention | diabetes is a risk factor for dementia (Crane PK et al., NEJM 2013); brain insulin resistance is confirmed in postmortem tissue from Alzheimer's patients (Talbot K et al., J Clin Invest 2012) |
| Hyperglycaemia is a modifiable risk factor for neurodegeneration | blood glucose can be influenced: minimise refined sugars and starches and take carbohydrates from whole sources | blood glucose level, even in the subdiabetic range, correlates directly with dementia risk in a prospective cohort (Crane PK et al., NEJM 2013, PMID 23924004[1]) |
| Gluten is not only about coeliac disease | helps avoid missing coeliac disease and gluten sensitivity: serological screening when there are symptoms, an elimination trial if suspicion remains | coeliac disease (1% of the population) is an autoimmune disease treated by lifelong gluten exclusion; in non-coeliac gluten sensitivity (NCGS, about 6% of the population) symptomatic patients without features of coeliac disease improve on a gluten-free diet and relapse on challenge (Volta U et al., BMC Med 2014) |
| Ketone bodies are an alternative fuel for the brain | when glucose utilisation is impaired, the brain can draw energy from ketone bodies, which are independent of insulin signalling | the brain in early Alzheimer's shows a deficit of glucose metabolism with preserved utilisation of ketone bodies ([11C]acetoacetate PET; Cunnane SC et al., Nat Rev Drug Discov 2020, PMID 32709961[2]); in an RCT of the ketogenic agent AC-1202 in 152 patients with mild to moderate Alzheimer's disease, the cognitive score on day 45 was better than with placebo (Henderson ST et al., Nutr Metab 2009, PMID 19664276[3]); the ketogenic diet has been a standard therapy for refractory paediatric epilepsy since the 1920s, with reliable efficacy |
What the book's ideas offer
Alzheimer's as "type 3 diabetes"
The strongest thesis of the book: Alzheimer's disease is in large part a metabolic disease of the brain associated with insulin resistance. The "type 3 diabetes" concept, proposed by Suzanne de la Monte (Brown University, J Diabetes Sci Technol 2008), describes how the Alzheimer's brain demonstrates the characteristic features of insulin resistance: reduced expression of insulin receptors in the hippocampus, impaired signalling, dysfunctional glucose metabolism (visible on FDG-PET 10–15 years before clinical symptoms).
APOE4 carriers carry a heightened predisposition to Alzheimer's, and this association is modified by metabolic factors (diabetes, obesity).
The relationship is bidirectional and mechanistically logical. Insulin resistance reduces glucose uptake by neurons (the brain accounts for 20% of whole-body glucose metabolism). Neurons enter an energy deficit. In parallel β-amyloid is a by-product of impaired APP processing under conditions of hyperglycaemia and oxidative stress. Chronic energy deficit plus β-amyloid accumulation gives clinical disease 15–30 years later.
Gluten and the gut
The second central thesis of the book: Perlmutter argues that gluten has a neuroinflammatory effect even in patients without coeliac disease. Beyond the data in the table, the following is well established: - Coeliac disease is a clinically reliable autoimmune disease with robust serological diagnosis (anti-tTG, anti-EMA, anti-DGP) and endoscopic confirmation. Treatment is lifelong gluten exclusion. This is mainstream medicine - Zonulin-mediated increases in intestinal permeability in susceptible individuals under a gluten load (Fasano A, Physiol Rev 2011, PMID 21248165[4]) — a defensible biological model
Ketones as an alternative fuel
The third idea is the ketogenic diet as a neuroprotective regime. The logic: when glucose utilisation is impaired (pre-diabetes, early neurodegeneration), the brain does not receive enough energy. Ketone bodies (β-hydroxybutyrate, acetoacetate) are an alternative energy substrate independent of insulin signalling.
How to apply it
What can be taken from Perlmutter's ideas in clinical practice:
| Marker | Target |
|---|---|
| HbA1c | < 5.4% |
| HOMA-IR | < 1.5 |
| ApoB | < 80 mg/dL |
| Omega-3 index | > 8% |
| 25(OH)D | 40–60 ng/mL |
Who should see a doctor first
The ketogenic diet has significant limitations: - Not suitable in hypothyroidism (low carbohydrate intake reduces T4-to-T3 conversion) - Risk of menstrual disturbance in women of reproductive age - Contraindicated in adrenal disease, glycogen storage disease, carnitine deficiency, and biliary disease - Long-term safety data in healthy adults are limited; there are signals of dyslipidaemia (rising ApoB in some patients), renal function disturbance and microbiome shifts
- Gluten: not grounds for self-exclusion without diagnosis — for a significant fraction of patients this creates nutritional risks without clinical benefit. Elimination trial with mandatory challenge — only under clinical supervision
- Dementia: for the treatment of established dementia the standard remains in neurology
- Blood sugar: if you don't have diabetes and your blood sugar is repeatedly below 3.0 mmol/L (54 mg/dL) or above 8.9 mmol/L (160 mg/dL) — see a doctor
Bottom line
What is strong in the book: the metabolic nature of Alzheimer's as type 3 diabetes; the link between HbA1c and neurodegeneration risk; the role of ketone utilisation in brain energetics; the idea that neurodegeneration is a process beginning decades before clinical signs and modifiable by metabolic means. The principal biological concepts — the link between metabolic health and the brain, the metabolic nature of Alzheimer's, gut-brain neuroactivity — are sound and merit serious attention.
The book is for a healthy person who wants to understand the metabolic roots of neurodegeneration and optimise their diet.
About the reviewer
Dr. Vladimir Pereligyn — endocrinologist. Functional medicine with a focus on preventive strategies: metabolic health, thyroid function, hormonal balance, and individualised risk profiling based on extended laboratory diagnostics. Consultations in person and online: universum.earth/consultation. App Store: Teremok (type 2 diabetes, remission).
Source
▸ Perlmutter D, Loberg K. Grain Brain: The Surprising Truth about Wheat, Carbs, and Sugar — Your Brain's Silent Killers. Little, Brown and Company, New York, 2013. ISBN 978-0316234801. 336 pages.
Further reading on the topics of this review: ▸ de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2008;2(6):1101-13. ▸ Crane PK, Walker R, Hubbard RA, et al. Glucose levels and risk of dementia. N Engl J Med 2013;369(6):540-8. PMID 23924004[1] ▸ Talbot K, Wang HY, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012;122(4):1316-38. ▸ Volta U, Bardella MT, Calabrò A, et al. An Italian prospective multicenter survey on patients suspected of having non-celiac gluten sensitivity. BMC Med 2014;12:85. ▸ Cunnane SC, Trushina E, Morland C, et al. Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov 2020;19(9):609-633. PMID 32709961[2]
References
Key facts
- Alzheimer's disease is in large part a metabolic disease of the brain associated with insulin resistance ('type 3 diabetes'); brain insulin resistance is confirmed in postmortem tissue from patients (Talbot K, J Clin Invest 2012).
- Hyperglycaemia is a modifiable risk factor for neurodegeneration: diabetes is a risk factor for dementia, and blood glucose even in the subdiabetic range correlates directly with dementia risk (Crane PK, NEJM 2013).
- Coeliac disease (1% of the population) is a reliable autoimmune disease and non-coeliac gluten sensitivity (about 6%) a clinically observable phenomenon; with symptoms, start with serological screening (anti-tTG IgA plus total IgA).
- Ketone bodies are an alternative brain energy substrate independent of insulin: their utilisation is preserved in early Alzheimer's, and in an RCT of the ketogenic agent AC-1202 in 152 patients with mild to moderate Alzheimer's disease, the cognitive score on day 45 was better than with placebo (Henderson ST et al., 2009).
- A practical minimum for the brain: HbA1c < 5.4%, HOMA-IR < 1.5, ApoB < 80 mg/dL, omega-3 index > 8%; minimise refined sugars and starches and take carbohydrates from whole sources.




